FDA Says Lux's Uveitis Treatment Luveniq Needs Another Clinical Trial
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Lux Biosciences will have to do another clinical trial - on top of three already completed Phase III studies - for FDA to consider approving its uveitis treatment Luveniq (voclosporin), the agency said in a "complete response" letter announced Aug. 4